Studies reveal that NNMT inhibitors double muscle strength gains and reduces muscle fat, offering a promising solution to age-related muscle loss.
Stan Watowich
Dr. Watowich is a faculty in the department of Biochemistry & Molecular Biology at the University of Texas Medical Branch. He is also Founder & CEO of Ridgeline Therapeutics, a Houston-based biotechnology company developing transformative drugs that enable adults to age stronger and live healthier. He is an accomplished entrepreneur, inventor, educator, researcher, and developer of world-class innovative resources, including the global “DiscoveryingDengueDrugs-Together” project with IBM and the DrugDiscovery@TACC supercomputer-based drug screening portal. Dr. Watowich graduated from Carleton College, received his Ph.D. in Physical Chemistry from the University of Chicago, and was a research fellow at Harvard University before migrating to Texas.